Table 2.
Characteristics of the analytic cohort after 3 months of treatment with cyclosporine or rituximab as part of the MENTOR trial
| Characteristics at 3 mo | Overall Cohort | No Remission at 12 mo | Remission at 12 mo |
|---|---|---|---|
| Albumin at 3 mo, g/dl | 3.0 (2.4–3.4) | 2.6 (2.3–3.0) | 3.2 (2.8–3.7) |
| Albumin change from baseline to 3 mo, g/dl | 0.4 (0.1–0.7) | 0.2 (0–0.4) | 0.6 (0.2–0.9) |
| Proteinuria at 3 mo, g/d | 6.5 (3.3–9.5) | 9.3 (6.5–12.1) | 3.6 (2.3–7.1) |
| Proteinuria change from baseline to 3 mo, g/d | −4.2 (−6.8 to −2) | −2.5 (−4.4 to 0.2) | −5.2 (−7.3 to −3.3) |
| Creatinine clearance at 3 mo, ml/min per 1.73 m2 | 80 (65–98) | 70 (47–94) | 86 (76–105) |
| Creatinine clearance change from baseline to 3 mo, ml/min per 1.73 m2 | −1 (−21 to 11) | −2 (−21 to 9) | 0 (−21 to 11) |
| PLA2R antibody level at 3 mo, RU/ml | 12 (2–84) | 95 (17–210) | 3 (0–19) |
| PLA2R antibody levels at 3 mo, n (%) | |||
| <14 RU/ml | 43 (51) | 8 (21) | 35 (75) |
| 14–20 RU/ml | 3 (4) | 2 (5) | 1 (2) |
| ≥20 RU/ml | 39 (46) | 28 (74) | 11 (23) |
| PLA2R antibody change from baseline to 3 mo, RU/ml | −136 (−321 to −57) | −234 (−419 to −80) | −82 (−170 to −51) |
Data are presented as count (frequency) or median (interquartile range). MENTOR, Membranous Nephropathy Trial Of Rituximab.